Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from BrokeragesMarket Beat·Aug 18 at 03:29 AMTSHA-0.33%
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6% - Here's WhyMarket Beat·Aug 13 at 02:40 PMTSHA-0.33%
Gil Blum Reaffirms Buy Rating on Taysha Gene Therapies, Maintains $12 Price Target Amid De-Risking Clinical MilestonesTip Ranks·Aug 12 at 05:45 AMTSHA-0.33%
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% UpsideTradingView·Aug 12 at 05:20 AMTSHA-0.33%
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPSMarket Beat·Aug 11 at 03:11 PMTSHA-0.33%
TSHA: TSHA-102 trials completed dosing; topline data and FDA feedback expected in 1H 2027Quartr·Aug 11 at 03:08 PMTSHA-0.33%
Taysha Gene Therapies grants new hire 144,000 RSUs, 92,400 stock options priced at $5.78PUBT·Aug 7 at 07:02 AMTSHA-0.33%
Taysha Gene Therapies to report Q2 results, host corporate update call and webcastPUBT·Aug 4 at 03:00 PMTSHA-0.33%
Taysha Gene Therapies taps Catalent for TSHA-102 Rett syndrome commercial manufacturing supportPUBT·Aug 3 at 07:02 AMTSHA-0.33%
